Steven M. Horwitz, MD - Advancing The Treatment Paradigm in Relapsed/Refractory B- and T-Cell Lymphoma: The Evolving Role of EZH1/2 Pathway Inhibitors

Please visit answersincme.com/HRM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cancerous lymphoma discusses EZH2 and EZH1 inhibitors for the management of relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas. Upon completion of this activity, participants should be better able to: Describe the rationale for exploring EZH 2 and EZH1 inhibitors for the management of relapsed or refractory (R/R) B-cell and T-cell non-Hodgkin lymphomas (NHLs); Explain the mechanism of action (MOA) of EZH2 and EZH1 inhibition; and Review the clinical profiles of approved and emerging EZH2 and EZH1 inhibitors for R/R B-cell and T-cell NHLs.